In contrast, blocking TGF-β using a neutralizing antibody, antisense oligonucleotides, inhibitors, or genetic deletion of receptors effectively alleviates the degree of renal fibrosis both in vivo and in vitro [7]. The gene discussed is TGFB1; the disease is renal fibrosis.